Neoadjuvant Abiraterone Prior to Surgery Beneficial in High-Risk Prostate Cancer
In a phase 2 trial, 44% of men who received abiraterone with or without cabazitaxel prior to radical prostatectomy for high-risk prostate cancer achieved a pathologic complete response or minimal residual disease.